SCHEMBL4663837

SCHEMBL4663837

O=CON(c1ccc(Nc2cc(-c3ccc(OCCN4CCCC4)cc3)ncn2)cc1)S(=O)(=O)c1ccc(F)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.45
NTRK1 P04629 1/20 0.43
CYP3A4 P08684 2/20 0.41
FGFR3 P22607 1/20 0.41
ABL1 P00519 8/20 0.39
BCR P11274 8/20 0.39
EGFR P00533 3/20 0.39
SRC P12931 1/20 0.37
MCHR1 Q99705 1/20 0.37
JAK2 O60674 2/20 0.37
JAK3 P52333 2/20 0.37
PTK2 Q05397 2/20 0.37
HRH3 Q9Y5N1 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667537 0.94 EGFR (0.41) AXLNTRK1CYP3A4FGFR3ABL1
SCHEMBL4665705 0.88 CYP3A4 (0.44) CYP3A4FGFR3ABL1BCRJAK2
SCHEMBL4663885 0.88 FGFR3 (0.41) AXLNTRK1CYP3A4FGFR3ABL1
SCHEMBL4665609 0.87 SRC (0.42) AXLNTRK1CYP3A4FGFR3ABL1
SCHEMBL4665882 0.87 ABL1 (0.42) AXLCYP3A4FGFR3ABL1BCR
SCHEMBL4665832 0.87 MEN1 (0.44) CYP3A4ABL1BCREGFRHRH3
SCHEMBL4665811 0.86 HRH3 (0.41) AXLCYP3A4FGFR3ABL1BCR
SCHEMBL4665757 0.85 HTR6 (0.35) AXLCYP3A4ABL1BCREGFR
Formic Acid SCHEMBL4663832 0.84 AXL (0.47) AXLNTRK1CYP3A4FGFR3ABL1
SCHEMBL4666086 0.84 HRH3 (0.44) CYP3A4FGFR3ABL1BCRHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 AXL 223/4885NTRK1 280/4885CYP3A4 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.